Michael R. Bishop

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole et al. · The Lancet · 2021 · 769 citations · Full text

Medicine, Hematology, Oncology +9

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Michael R. Bishop, Michael Dickinson, Duncan Purtill et al. · New England Journal of Medicine · 2021 · 520 citations · Full text

Medicine, Hematology, Oncology +9

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

Selina M. Luger, Olle Ringdén, M-J Zhang et al. · Bone Marrow Transplantation · 2011 · 275 citations · Full text

Medicine, Immunology, Oncology +6

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Marcela V. Maus, S. Alexander, Michael R. Bishop et al. · Journal for ImmunoTherapy of Cancer · 2020 · 269 citations · Full text

Life Sciences, Immunology, Oncology +17

Allogeneic bone marrow transplantation for low-grade lymphoma.

Koen van Besien, Kathleen A. Sobocinski, Philip A. Rowlings et al. · PubMed · 1998 · 265 citations

Medicine, Hematology, Oncology +13